Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients

NCT00382590 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Acute Myelogenous Leukemia
Myelodysplastic Syndrome
Leukemia

Interventions

DRUG: 5-Azacytidine
DRUG: Ara-C
DRUG: Valproic Acid (VPA)

Sponsor

M.D. Anderson Cancer Center